$GHRS News

GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

HC Wainwright & Co. Maintains Buy on GH Research, Lowers Price Target to $65

These Analysts Revise Their Forecasts On GH Research After Q1 Results

Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $35

Citizens Maintains Market Outperform on GH Research, Lowers Price Target to $39

GH Research Q1 EPS $(0.31) Misses $(0.28) Estimate

GH Research Announces Pricing of $117.5 Million Underwritten Offering

GH Research Prices ~$117.5M Offering Of 6.528M Shares At $18/Share

FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit.

‘Can I have some, please?’: Trump jokes as he signs psychedelics order after Joe Rogan push. These stocks soar

How Trump Sent Psychedelics-Tied Compass Pathways And Others Flying

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

GH Research: WH Decision On Psychedelics To Treat Depression Makes Bull Case

Psychedelic stocks soar after Trump signs executive order to fast-track treatments

Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones

Here's Why We're Not At All Concerned With GH Research's (NASDAQ:GHRS) Cash Burn Situation

Will Psychedelic Stocks Have A Trippy Ride Under RFK Jr.?

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD

GH Research Announces Two-Peer Reviewed Publications From Its Phase 2B Clinical Program Of GH001 For Treatment-Resistant Depression

What Does GH Research PLC (GHRS)’s Clinical Progress Updates Say?